Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 4
2016 2
2017 1
2018 4
2019 6
2020 7
2021 4
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ribera JM, García-Calduch O, Ribera J, Montesinos P, Cano-Ferri I, Martínez P, Esteve J, Esteban D, García-Fortes M, Alonso N, González-Campos J, Bermúdez A, Torrent A, Genescà E, Mercadal S, Martínez-Lopez J, García-Sanz R. Ribera JM, et al. Among authors: genesca e. Blood Adv. 2022 Sep 27;6(18):5395-5402. doi: 10.1182/bloodadvances.2022007764. Blood Adv. 2022. PMID: 35675590 Free PMC article.
TIM3, a human acute myeloid leukemia stem cell marker, does not enrich for leukemia-initiating stem cells in B-cell acute lymphoblastic leukemia.
Bueno C, Martínez A, Romecin PA, Zanetti SR, Tirtakusuma R, Genesca E, Camós M, Ramírez-Orellana M, Anguita E, Ballerini P, Locatelli F, Fuster JL, Menéndez P. Bueno C, et al. Among authors: genesca e. Haematologica. 2023 Aug 1;108(8):2229-2233. doi: 10.3324/haematol.2022.282394. Haematologica. 2023. PMID: 36655434 Free PMC article. No abstract available.
Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials.
González-Gil C, Morgades M, Lopes T, Fuster-Tormo F, García-Chica J, Zhao R, Montesinos P, Torrent A, Diaz-Beya M, Coll R, Hermosín L, Mercadal S, González-Campos J, Zamora L, Artola T, Vall-Llovera F, Tormo M, Gil-Cortés C, Barba P, Novo A, Ribera J, Bernal T, De Ugarriza PL, Queipo MP, Martínez-Sánchez P, Giménez A, González-Martínez T, Cladera A, Cervera J, Fernández-Martín R, Ardaiz MÁ, Vidal MJ, Baena Á, López-Bigas N, Bigas A, Maciejewski J, Orfao A, Ribera JM, Genescà E. González-Gil C, et al. Among authors: genesca e. Haematologica. 2023 Apr 1;108(4):969-980. doi: 10.3324/haematol.2022.281196. Haematologica. 2023. PMID: 36325893 Free PMC article.
33 results